Developing new indications
for approved medicines in hematological malignancies
using a proprietary continuous delivery platform.

Targeted continuous delivery

We reimagine FDA-approved medicines and leverage our delivery system to establish new profiles. Our platform technology allows for lower drug exposure and the potential for improved efficacy.


We are building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers. Learn more about career opportunities at Starton.

News and Events

January 11, 2021

Starton Therapeutics Selects Formulation for Continuous Subcutaneous Lenalidomide Delivery System for CLL Treatment 

Additional patent application filed for novel parenteral formulation in development for Chronic Lymphocytic Leukemia (CLL) PARAMUS, N.J., January 11, 2021 – Starton Therapeutics Inc. (“Starton” or the “Company”), a…

September 14, 2020

Keith Darragh Joins Starton Therapeutics as Chief Financial Officer

NEW YORK, N.Y., September 14, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology powering continuous delivery of approved drugs for novel indications, announced today…